Rasagiline
- Generic Name
- Rasagiline
- Brand Names
- Azilect, Rasagiline Mylan, Rasagiline ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N
- CAS Number
- 136236-51-6
- Unique Ingredient Identifier
- 003N66TS6T
- Background
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
- Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
- Associated Conditions
- Parkinson's Disease (PD)
Pain in Parkinson's Disease With Motor Fluctuations.
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 48
- Registration Number
- NCT03648671
- Locations
- 🇮🇹
Azienda ospedaliera universitaria integrata verona, Verona, Italy
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
- Conditions
- Parkinson DiseaseEarly Parkinson's Disease
- Interventions
- Drug: P2B001 0.6/0.75 mg
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Pharma Two B Ltd.
- Target Recruit Count
- 544
- Registration Number
- NCT03329508
- Locations
- 🇺🇸
P2B001/003 site Boca Raton, Boca Raton, Florida, United States
🇺🇸P2B001/003 Study site little Rock, Little Rock, Arkansas, United States
🇺🇸P2B001/003 Site Scottsdale, Scottsdale, Arizona, United States
Image Parkinson's Disease Progression Study
- Conditions
- Parkinson's Disease
- Interventions
- Other: PlaceboDevice: Magnetic Resonance ImagingDevice: functional Magnetic Resonance ImagingOther: Physical Function Performance Test
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 96
- Registration Number
- NCT02789020
- Locations
- 🇺🇸
Laboratory for Rehabilitation Neuroscience, Gainesville, Florida, United States
Azilect® In Wearing-Off (AIWO)
- Conditions
- Parkinson's Disease
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Teva Pharma GmbH
- Target Recruit Count
- 261
- Registration Number
- NCT02384512
- Locations
- 🇩🇪
Teva Investigational Sites, Zwickau, Germany
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT02359552
- Locations
- 🇺🇸
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States
🇺🇸Cleveland Clinic Lakewood Hospital, Lakewood, Ohio, United States
🇺🇸Cleveland Clinic Main Campus, Cleveland, Ohio, United States
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 244
- Registration Number
- NCT02337725
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 45
- Registration Number
- NCT02278588
- Locations
- 🇺🇸
University at Buffalo, Buffalo, New York, United States
Ambulosono Rasagiline Musical Walking Study
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 60
- Registration Number
- NCT02207387
- Locations
- 🇨🇦
Pacific Parkinson's Research Centre, Vancouver, British Columbia, Canada
Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 23
- Registration Number
- NCT02068625
- Locations
- 🇨🇭
Department of Ophthalmology, Bern University Hospital, Bern, Switzerland
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01879748
- Locations
- 🇺🇸
Teva Investigational Site 10738, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.